By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Arena and Qnexa Get Good News
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Arena and Qnexa Get Good News
Business

Arena and Qnexa Get Good News

PatrickDriscoll
PatrickDriscoll
Share
2 Min Read
SHARE
In a continued trend in which the FDA seems to be working toward rapprochement with the previously beleaguered obesity drug industry, this week the agency has in one case asked Qnexa manufacturer Vivus on Monday to remove the contraindication for use of the drug in women of child-bearing potential (although keep in place the contraindication for women actually pregnant), a move that increases the potential obesity drug patient population and the aura of “safety” surrounding Qnexa. 

 

In a continued trend in which the FDA seems to be working toward rapprochement with the previously beleaguered obesity drug industry, this week the agency has in one case asked Qnexa manufacturer Vivus on Monday to remove the contraindication for use of the drug in women of child-bearing potential (although keep in place the contraindication for women actually pregnant), a move that increases the potential obesity drug patient population and the aura of “safety” surrounding Qnexa. 

 

http://www.reuters.com/article/2012/01/09/us-vivus-idUSTRE8081LI20120109

 

In another case, the FDA notified Arena Pharmaceuticals that it has accepted the resubmitted drug application for the company’s obesity drug, Lorcaserin.

 

http://online.wsj.com/article/BT-CO-20120110-706510.html

 

 

Needless to say, both Vivus’ and Arena’s stock price took sharp jumps on the news.
The aggregate worldwide market for obesity drugs could reach $1.8 billion by 2019 if drug approvals happen as forecast for these and other obesity drugs. (See “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019“.

 

TAGGED:obesityQnexaVIVUS
Share This Article
Facebook Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

BusinessTechnology

Leveraging Digital Signage for Patient Education,Marketing and Service Improvement

December 21, 2012

Debate Over Doctor Shortages

August 17, 2012

CEO Interview: Michael Moe On GSV Capital, A New Vehicle To Finance Growth Companies

July 4, 2011

How To Get Rid Of Belly Fat: The Roles Diet, Stress, And Exercise Play In Belly Fat Reduction (Part 4)

June 6, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?